Ola Pani is a chemotherapeutic agent for the treatment of recurrent or advanced ovarian cancer and metastatic breast cancer in patients with specific mutations and previous history of chemotherapy. Olapani is sold under the lynparza brand in the form of oral tablets and was originally designated as maintenance therapy or monotherapy for adult patients with recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer.